Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

NCT04686383 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Resistant or Refractory Solid Tumors

Interventions

DRUG: CAL056 mesylate

Sponsor

Calgent Biotechnology Co., Ltd